



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Padigaru, et al

SERIAL NUMBER: 10/092,900

EXAMINER: Kapust, Rachel B.

FILING DATE: March 07, 2002

ART UNIT: 1647

FOR: Novel Proteins And Nucleic Acids Encoding Same

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Boston, Massachusetts  
May 24, 2004


**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Amendment and Response to Office Action (10 pages); and
2. Return postcard.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.21402-290C.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer No. 30623**

Dated: May 24, 2004


05/26/04

1647

John

Express Mail Label No.: EV138523101US  
Date of Deposit: May 24, 2004

Attorney Docket No. 21402-290C (Cura 590C)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Padigaru, et al

SERIAL NUMBER: 10/092,900

EXAMINER: Kapust, Rachel B.

FILING DATE: March 07, 2002

ART UNIT: 1647

FOR: Novel Proteins And Nucleic Acids Encoding Same

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Boston, Massachusetts  
May 24, 2004

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

This paper is in response to the February 24, 2004 Office Action in the above-referenced application. While Applicants believe that no additional fee is due as a result of this filing, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-290C (Cura 590C).

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 3 of this paper.

**Remarks** begin on page 5 of this paper.